Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brent Davidson

Obstetrics & Gynecology Detroit, MI Medical Doctor

NPI 1336216480 CMS profile 15076

2799 W Grand Blvd, Detroit, MI 48202

Open in the dashboard

General payments

$170,797

240 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brent Davidson of Detroit, MI is reported in the CMS Open Payments database as having received $170,797 across 240 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,651 19
2024 General $22,097 19
2023 General $24,313 29
2022 General $21,395 41
2021 General $25,160 39
2020 General $30,014 39
2019 General $26,166 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brent Davidson
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Brent Davidson were reported at $21,651. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Brent Davidson Obstetrics & Gynecology median Middle half National median
2019 $26,166 $172 $62–$391 $163
2020 $30,014 $94 $36–$222 $114
2021 $25,160 $136 $42–$369 $132
2022 $21,395 $160 $50–$433 $149
2023 $24,313 $169 $56–$423 $160
2024 $22,097 $152 $50–$371 $164
2025 $21,651 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gen-Probe, Inc. $60,914 28 payments
  2. Organon LLC $31,977 64 payments
  3. AbbVie, Inc. $25,371 27 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $20,437 45 payments
  5. Merck Sharp & Dohme Corporation $18,106 27 payments
  6. Hologic, LLC $11,026 29 payments
  7. Duchesnay USA Incorporated $1,931 11 payments
  8. Gen-Probe Sales & Service, Inc. $434 2 payments
  9. Covidien LP $400 1 payment
  10. Medtronic, Inc. $200 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $82,479 69 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $48,620 32 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $24,671 34 payments
  4. Travel and Lodging $9,740 49 payments
  5. Honoraria $2,925 2 payments
  6. Food and Beverage $2,325 47 payments
  7. Education $35 7 payments
Products named General payments · program years 2019–2025
  1. Aptima $63,712 43 payments
  2. NEXPLANON Etonogestrel $24,827 46 payments
  3. NEXPLANON Womens Health $18,106 27 payments
  4. ORIAHNN $14,025 11 payments
  5. Kyleena $11,432 23 payments
  6. Mirena $11,432 23 payments
  7. Skyla $8,632 18 payments
  8. Nexplanon Womens Health $7,036 17 payments
  9. THINPREP 2000 PROCESSOR $6,716 7 payments
  10. Sexually Transmitted Infectious Disease $4,527 11 payments
  11. Other $10,584 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

407

Median for Obstetrics & Gynecology: 65

Drug cost

$76,065

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

53.8%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 34 $18,538
Prempro Estrogen,con/M-Progest Acet Brand 29 $18,507
Estring Estradiol Brand 16 $8,189
Estradiol Generic 86 $6,947
Osphena Ospemifene Brand 12 $5,216
Combipatch Estradiol/Norethindrone Acet Brand 12 $3,997
Yuvafem Estradiol Brand 22 $3,385
Estradiol (Twice Weekly) Estradiol Brand 30 $3,019
Valacyclovir Valacyclovir Hcl Brand 32 $2,354
Estradiol (Once Weekly) Estradiol Brand 13 $1,807

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$8,098

Medicare's payments for the services billed

Medicare patients

120

Average age 69

Services billed

163

120 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 47%
Arthritis 45%
Osteoporosis 24%
Depression 19%
Diabetes 18%
Cancer 16%
Chronic kidney disease 10%
Ischemic heart disease 9%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

240 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record